Polyclonal Rabbit AFF3 Antibody
- Known as:
- Polyclonal Rabbit AFF3 Antibody
- Catalog number:
- abx038302
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Abbexa
- Gene target:
- Polyclonal Rabbit AFF3 Antibody
Related genes to: Polyclonal Rabbit AFF3 Antibody
- Gene:
- AFF3 NIH gene
- Name:
- AF4/FMR2 family member 3
- Previous symbol:
- LAF4
- Synonyms:
- MLLT2-like
- Chromosome:
- 2q11.2
- Locus Type:
- gene with protein product
- Date approved:
- 1998-03-27
- Date modifiied:
- 2016-10-05
Related products to: Polyclonal Rabbit AFF3 Antibody
Related articles to: Polyclonal Rabbit AFF3 Antibody
- Ossifying fibromyxoid tumor (OFMT) is a rare mesenchymal neoplasm of uncertain lineage of differentiation driven by a broad spectrum of gene fusions. It manifests primarily in soft tissues of the extremities. In this study, we performed a comprehensive clinicopathological, molecular-genetic, and epigenetic analysis of 70 cases of OFMT, with a specific focus on rare fusion subtypes, particularly ZC3H7B::BCOR, PHF1::TFE3 and MEAF6::PHF1. In addition, we included seven tumors with novel fusions, namely AFF3::PHF1, PHF1::KLF15, PHF1::PRKAG1, CREBBP::PHF1, EPC1::BMI1, MEAF6::BCOR, and EP300::BCORL1. The clinicopathological characteristics revealed a correlation between specific fusions and aggressive clinical behavior; notably, tumors with ZC3H7B::BCOR fusions were always classified as morphologically atypical or malignant and were associated with significantly higher recurrence and metastatic rates compared to other fusion groups, particularly EP400::PHF1. Immunohistochemical analysis further revealed a distinct immunophenotype in the ZC3H7B::BCOR group. While immunopositivity for cytokeratins and myogenic markers was observed in approximately one-quarter and more than one-third of OFMT cases overall, respectively, ZC3H7B::BCOR-rearranged tumors were negative for both. In contrast, the majority showed immunopositivity for pan-Trk. Additionally, DNA methylation profiling distinguished ZC3H7B::BCOR-rearranged cases from other fusion-positive OFMT, whereas the former clustered closely with a subset of high-grade endometrial stromal sarcomas. This study supports the recognition of ZC3H7B::BCOR-positive tumors as a distinct clinicopathological entity, contributing to the refined molecular taxonomy of this neoplasm. - Source: PubMed
Publication date: 2026/06/16
Klubíčková NatálieDermawan Josephine KAmeline BaptisteMartínek PetrVaněček TomášHájková VeronikaPtáková NikolaGrossmann PetrŠteiner PetrKormunda StanislavPerret Raul ELe Loarer FrançoisDehner CarinaTorres-Mora JorgeGross John MChrisinger John S ACharville GregoryKosemehmetoglu KemalWangsiricharoen SintawatMeis JeanneŠpůrková ZuzanaZámečník MichalZambo Iva StaniczkováKlinger Tomᚊvajdler MariánKinkor ZdeněkMichalová KvětoslavaBaumhoer DanielMichal MichalAntonescu Cristina RMichal Michael - Tuberculosis (TB) is a severe respiratory illness that can lead to opportunistic infections in individuals with weakened immune systems. Accurate diagnosis and monitoring of treatment responses are essential. In this study, we analyzed the miRNA and mRNA profiles of 12 patients with active TB (ATB) before and after treatment. - Source: PubMed
Publication date: 2026/06/03
Park HeechulLee Eun JuPark SunyoungPark Sung-BaeKang Yun-JeongLee JiyoungWhang JakeKang Young AeKim SunghyunLee HyejonKim Jungho - KMT2A-rearranged (KMT2A-r) acute lymphoblastic leukemia (ALL), particularly in infants, represents one of the most aggressive pediatric hematological malignancies with a historically dismal prognosis. While KMT2A-AFF1 (t(4;11)) is the most prevalent fusion, a diverse array of partner genes exists, each conferring distinct biological and clinical features. This review focuses on the rare but clinically significant KMT2A-AFF3 subtype, which arises from the t(2;11)(q11.2;q23) chromosomal translocation. This review summarizes the molecular pathogenesis driven by the KMT2A-AFF3 fusion oncoprotein, which functions as an aberrant transcriptional complex. This complex hijacks essential epigenetic machinery, including the recruitment of DOT1L and interaction with Menin, leading to pathogenic histone modifications (e.g., H3K79 hypermethylation) and the subsequent upregulation of critical target genes, notably the HOXA cluster and MEIS1, thereby enforcing a B-lymphoid differentiation arrest at the pro-B/pre-B stage. Clinically, KMT2A-AFF3 ALL is characterized by high-risk features, including infant onset, hyperleukocytosis, central nervous system (CNS) involvement, and a distinct CD10-negative immunophenotype. This review highlights the evidence defining its poor prognosis, which is primarily driven by profound chemoresistance to conventional therapies, including glucocorticoids. Finally, we discuss the rapidly evolving therapeutic landscape, detailing the limitations of standard intensive chemotherapy and the immense promise of novel targeted strategies, such as Menin inhibitors (e.g., Revumenib), DOT1L inhibitors, and immunotherapies (e.g., CAR-T cells, Blinatumomab), which hold the potential to revolutionize outcomes for this high-risk leukemia subtype. - Source: PubMed
Publication date: 2025/11/26
Zhang YaweiLiang Juan - A major challenge to global vector control efforts is the increasing resistance of Aedes mosquitoes to conventional insecticides. Since they are the main vectors of dengue, Zika, and chikungunya, sustainable and environmentally friendly approaches are essential for vector control. Attractive toxic sugar baits (ATSBs) take advantage of mosquitoes' propensity for sugar and can offer an alternative strategy. However, further research is needed to investigate the performance of ATSBs, especially in determining and assessing attractant combinations that might increase mosquito attraction and feeding efficiency. - Source: PubMed
Publication date: 2026/01/05
Ayub Noor MuokhniKassim Nur Faeza AbuSabar SumiyyahHashim Nur AidaLalung JaparengSulaiman Shaida FarizaAbuelmaali Sara AWebb Cameron E - Colorectal cancer (CRC) is a globally prevalent malignancy associated with high mortality rates. Despite the existence of various treatment modalities, the prognosis for CRC remains relatively poor. This study aims to explore the role of RNA-binding proteins (RBPs) in CRC progression and their potential as prognostic biomarkers and therapeutic targets. We first identified 166 prognosis-related RBPs, including LIN28B, PPARGC1A, RBM47, and AFF3, by performing univariate Cox regression analysis on bulk transcriptomic and clinical data from The Cancer Genome Atlas (TCGA). Next, single-cell RNA sequencing data from normal, adenoma, and CRC tissues of four patients were analyzed to determine cell type-specific expression patterns of RBPs. Ten upregulated RBPs (HSPB1, RBM47, HMGN2, BRD2, BST2, RBM6, YBX3, CANX, PLEC, and RNASET2) were identified as CRC-associated. Among them, HSPB1, RBM47, HMGN2, BRD2, BST2, and PLEC were predominantly expressed in epithelial cell subsets, whereas RNASET2, RBM6, YBX3, and G3BP2 showed higher expression in T cell subpopulations. Aberrant expression of these RBPs was significantly associated with clinical features such as age, cancer stage, and overall survival ( < 0.05). To validate the above findings, we performed qRT-PCR experiments on 15 paired CRC tumor and adjacent normal tissue samples. The results showed that the expression levels of CANX, RNASET2, YBX3, and BST2 were significantly higher in tumor tissues compared to adjacent normal tissues. Furthermore, we validated the expression levels and prognostic significance of these genes using the TCGA-COAD and READ cohorts, and found that their high expression was significantly associated with poorer overall survival. We suggest that RBPs may influence the occurrence and progression of CRC by affecting epithelial cells and T-cell subtypes, thus serving as promising prognostic biomarkers and potential targets for cancer immunotherapy in CRC. - Source: PubMed
Publication date: 2025/11/27
Lin MengxinWeng ZongqiLin YuyuanLai JinhongXu MeifangWang KangmeiChen XianqiangChen HongbinPan Jie